ONWARD Medical Reports EUR 2.5M Revenue in Q3 2026, Strong Clinical Progress

ONWARD Medical N.V. reported revenue of EUR 2.5 million for Q3 2026, driven by significant commercial traction and robust clinical execution. The company has expanded its ARC-EX Systems to over 170 clinics globally, marking a 120% growth year-over-year.

In terms of clinical progress, ONWARD continues its Empower BP global pivotal study, enrolling 31 participants across 16 sites in the US, Canada, and Germany. Notably, the company achieved first-in-human use of ARC-IM Therapy for bladder control after spinal cord injury.

Financially, ONWARD maintained a cash balance of EUR 73.4 million and secured a financing agreement for up to EUR 50 million with BlackRock-managed funds.

The company remains committed to advancing therapies to restore movement and function for individuals with spinal cord injuries through rigorous clinical studies and strategic growth initiatives.